Paul W. Noble focuses on Idiopathic pulmonary fibrosis, Internal medicine, Immunology, Cell biology and Pulmonary fibrosis. His research in Idiopathic pulmonary fibrosis intersects with topics in Physical therapy, Quality of life and Clinical trial. His studies deal with areas such as Gastroenterology and Surgery as well as Internal medicine.
Paul W. Noble has researched Gastroenterology in several fields, including Nintedanib and Pirfenidone. His studies in Immunology integrate themes in fields like Fibrosis, Cancer research and Lung. His studies deal with areas such as Alveolar cells, Stromal cell, Biochemistry and Cellular differentiation as well as Cell biology.
The scientist’s investigation covers issues in Idiopathic pulmonary fibrosis, Internal medicine, Immunology, Pathology and Pirfenidone. His Idiopathic pulmonary fibrosis research incorporates themes from Adverse effect, Pulmonary fibrosis, Clinical trial and Interstitial lung disease. His Internal medicine research includes themes of Gastroenterology and Surgery.
Paul W. Noble combines subjects such as Lung injury, Macrophage and Cell biology with his study of Immunology. His Pirfenidone research integrates issues from Nintedanib and Cardiology. His biological study spans a wide range of topics, including Molecular biology and Cytokine.
Paul W. Noble spends much of his time researching Idiopathic pulmonary fibrosis, Internal medicine, Pirfenidone, Lung and Pulmonary fibrosis. His research in Idiopathic pulmonary fibrosis intersects with topics in Epithelium, Vital capacity, Surgery, Pulmonary function testing and Interstitial lung disease. Much of his study explores Internal medicine relationship to Gastroenterology.
His research integrates issues of Physiology, Discontinuation, Lung function and Cardiology in his study of Pirfenidone. The various areas that Paul W. Noble examines in his Lung study include Cancer research, Stem cell, Immunology and Transcriptome. His Pulmonary fibrosis research focuses on subjects like Lung injury, which are linked to Lung fibrosis.
His primary areas of study are Idiopathic pulmonary fibrosis, Lung, Pulmonary fibrosis, Fibrosis and Internal medicine. His research ties Disease and Idiopathic pulmonary fibrosis together. His Pulmonary fibrosis study incorporates themes from Fibroblast, Lung injury and Immunology.
His Fibrosis study combines topics from a wide range of disciplines, such as Cancer research, Glycosaminoglycan and Hyaluronan Synthase 2. In his research on the topic of Internal medicine, Vital capacity and Interstitial lung disease is strongly related with Surgery. His study in Pathology is interdisciplinary in nature, drawing from both Bronchoalveolar lavage and Stem cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias
William D. Travis;Talmadge E. King;Eric D. Bateman;David A. Lynch.
American Journal of Respiratory and Critical Care Medicine (2002)
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi;Roland M. du Bois;Ganesh Raghu;Arata Azuma.
The New England Journal of Medicine (2014)
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King;Williamson Z. Bradford;Socorro Castro-Bernardini;Elizabeth A. Fagan.
The New England Journal of Medicine (2014)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble;Carlo Albera;Williamson Z Bradford;Ulrich Costabel.
The Lancet (2011)
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
R. J. M. Snijders;P. Noble;N. Sebire;A. Souka.
The Lancet (1998)
Leptin regulates proinflammatory immune responses
S. Loffreda;S. Q. Yang;H. Z. Lin;C. L. Karp.
The FASEB Journal (1998)
Regulation of lung injury and repair by Toll-like receptors and hyaluronan.
Dianhua Jiang;Jiurong Liang;Juan Fan;Shuang Yu.
Nature Medicine (2005)
Type 2 alveolar cells are stem cells in adult lung
Christina E. Barkauskas;Michael J. Cronce;Craig R. Rackley;Emily J. Bowie.
Journal of Clinical Investigation (2013)
Signaling properties of hyaluronan receptors.
Eva A. Turley;Paul W. Noble;Lilly Y.W. Bourguignon.
Journal of Biological Chemistry (2002)
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi;Ulrich Costabel;Moises Selman;Dong Soon Kim.
The New England Journal of Medicine (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: